Literature DB >> 15305378

EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR).

Lorella Bonaccorsi1, Vinicio Carloni, Monica Muratori, Lucia Formigli, Sandra Zecchi, Gianni Forti, Elisabetta Baldi.   

Abstract

We previously demonstrated that expression of androgen receptor (AR) by transfection of the androgen-independent prostate cancer cell line PC3 decreases invasion and adhesion of these cells (PC3-AR) through modulation of alpha6beta4 integrin expression. The treatment with androgens further reduced invasion of the cells without modifying alpha6beta4 expression, suggesting an interference with the invasion process by androgens. Here, we investigated EGF-mediated signal transduction processes that lead to invasion in PC3-AR cells. We show that EGF-induced EGFR autotransphosphorylation is reduced in PC3-AR cells compared to PC3 cells transfected only with the vector (PC3-Neo). EGF-stimulated PI3K activity, a key signaling pathway for invasion of these cells, and EGF-PI3K interaction are also decreased in PC3-AR cells and further reduced by treatment with androgen. Finally, we show that EGFR internalization process was reduced in PC3-AR and LNCaP cells compared to PC3-Neo. Investigations on the location of AR in PC3-AR transfected cells were also conducted. Immunoconfocal microscopy and coimminoprecipitation studies demonstrated the presence of an interaction between EGFR and AR at membrane level in PC3-AR and LNCaP cells. In conclusion, our results suggest that the expression of AR by transfection in PC3 cells confers a less-malignant phenotype by interfering with EGFR signaling leading to invasion through a mechanism involving an interaction between AR and EGFR. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15305378     DOI: 10.1002/ijc.20362

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

1.  Expression of ezrin and moesin in primary breast carcinoma and matched lymph node metastases.

Authors:  M Bartova; J Hlavaty; Y Tan; C Singer; K Pohlodek; J Luha; I Walter
Journal:  Clin Exp Metastasis       Date:  2017-06-17       Impact factor: 5.150

Review 2.  Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance.

Authors:  Shaun McKenzie; Natasha Kyprianou
Journal:  J Cell Biochem       Date:  2006-01-01       Impact factor: 4.429

Review 3.  Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.

Authors:  Meng-Lei Zhu; Natasha Kyprianou
Journal:  Endocr Relat Cancer       Date:  2008-07-30       Impact factor: 5.678

Review 4.  Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.

Authors:  A M Traish; A Morgentaler
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

5.  Gender-related survival differences associated with polymorphic variants of estrogen receptor-β (ERβ) in patients with metastatic colon cancer.

Authors:  O A Press; W Zhang; M A Gordon; D Yang; C A Haiman; M Azuma; S Iqbal; H-J Lenz
Journal:  Pharmacogenomics J       Date:  2010-06-15       Impact factor: 3.550

6.  Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib.

Authors:  Giulia Pinton; Warren Thomas; Paolo Bellini; Arcangela Gabriella Manente; Roberto E Favoni; Brian J Harvey; Luciano Mutti; Laura Moro
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

7.  Suppression of androgen receptor enhances the self-renewal of mesenchymal stem cells through elevated expression of EGFR.

Authors:  Chiung-Kuei Huang; Meng-Yin Tsai; Jie Luo; Hong-Yo Kang; Soo Ok Lee; Chawnshang Chang
Journal:  Biochim Biophys Acta       Date:  2013-01-17

Review 8.  Stroma-epithelium crosstalk in prostate cancer.

Authors:  Yi-Nong Niu; Shu-Jie Xia
Journal:  Asian J Androl       Date:  2008-12-22       Impact factor: 3.285

9.  Integrin involvement in freeze resistance of androgen-insensitive prostate cancer.

Authors:  J G Baust; D P Klossner; R G Vanbuskirk; A A Gage; V Mouraviev; T J Polascik; J M Baust
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-01-12       Impact factor: 5.554

10.  Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response.

Authors:  Brigette B Y Ma; Vivian W Y Lui; Fan Fong Poon; S C Cesar Wong; Ka Fai To; Elaine Wong; Honglin Chen; Kwok Wai Lo; Qian Tao; Anthony T C Chan; Margaret Heung Ling Ng; Suk Hang Cheng
Journal:  Invest New Drugs       Date:  2009-09-16       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.